Review



mouse anti human cd169 fitc  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Bio-Rad mouse anti human cd169 fitc
    Figure 1. <t>CD169-expressing</t> phagocytes are increased in the circulation and CNS of EAE animals. (a and b) Spinal cord tissue of EAE animals (20 dpi) stained for (a) CD169 and Iba1 or (b) CD169 and CD11b/c (both 20× magnification). (c) Spinal cord tissue of EAE animals (30 dpi) stained for CD169 and Iba1 (40× magnification). (d) Quantification of the amount of CD169+ cells per image and (e) the percentage of Iba1+ cells expressing CD169 in spinal cord tissue of control and EAE mice (acute (20 dpi) and chronic phase (30 dpi)). For quantification, 20 images per animal with 9 animals per time point were used (20× magnification). (f and g) PBMC isolated from control (n = 7) and EAE mice (acute phase (20 dpi), n = 6; chronic phase (30 dpi), n = 9) were stained for CD14 and CD169. Flow cytometry was used to assess the (f) % of CD14+ cells expressing CD169 and (g) the abundance of CD169 on these cells. Data are presented as mean ± SEM.
    Mouse Anti Human Cd169 Fitc, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human cd169 fitc/product/Bio-Rad
    Average 92 stars, based on 24 article reviews
    mouse anti human cd169 fitc - by Bioz Stars, 2026-03
    92/100 stars

    Images

    1) Product Images from "CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis."

    Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

    Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

    doi: 10.1177/1352458517698759

    Figure 1. CD169-expressing phagocytes are increased in the circulation and CNS of EAE animals. (a and b) Spinal cord tissue of EAE animals (20 dpi) stained for (a) CD169 and Iba1 or (b) CD169 and CD11b/c (both 20× magnification). (c) Spinal cord tissue of EAE animals (30 dpi) stained for CD169 and Iba1 (40× magnification). (d) Quantification of the amount of CD169+ cells per image and (e) the percentage of Iba1+ cells expressing CD169 in spinal cord tissue of control and EAE mice (acute (20 dpi) and chronic phase (30 dpi)). For quantification, 20 images per animal with 9 animals per time point were used (20× magnification). (f and g) PBMC isolated from control (n = 7) and EAE mice (acute phase (20 dpi), n = 6; chronic phase (30 dpi), n = 9) were stained for CD14 and CD169. Flow cytometry was used to assess the (f) % of CD14+ cells expressing CD169 and (g) the abundance of CD169 on these cells. Data are presented as mean ± SEM.
    Figure Legend Snippet: Figure 1. CD169-expressing phagocytes are increased in the circulation and CNS of EAE animals. (a and b) Spinal cord tissue of EAE animals (20 dpi) stained for (a) CD169 and Iba1 or (b) CD169 and CD11b/c (both 20× magnification). (c) Spinal cord tissue of EAE animals (30 dpi) stained for CD169 and Iba1 (40× magnification). (d) Quantification of the amount of CD169+ cells per image and (e) the percentage of Iba1+ cells expressing CD169 in spinal cord tissue of control and EAE mice (acute (20 dpi) and chronic phase (30 dpi)). For quantification, 20 images per animal with 9 animals per time point were used (20× magnification). (f and g) PBMC isolated from control (n = 7) and EAE mice (acute phase (20 dpi), n = 6; chronic phase (30 dpi), n = 9) were stained for CD14 and CD169. Flow cytometry was used to assess the (f) % of CD14+ cells expressing CD169 and (g) the abundance of CD169 on these cells. Data are presented as mean ± SEM.

    Techniques Used: Expressing, Staining, Control, Isolation, Flow Cytometry

    Figure 2. Transient depletion of CD169-expressing cells reduces EAE severity. (a) CD169-DTR mice and WT mice were sacrificed 2 or 8 days after intraperitoneal DTR administration. Splenic sections were stained with CD169 and DAPI (20× magnification). One representative image is shown. (b) Spinal cord tissue of PBS- and DT-treated CD169- DTR EAE animals (30 dpi) stained for CD169 and CD11b/c (20× magnification). EAE animals were treated with PBS or DT every other 5 days, starting 5 dpi. (c) Images show CD169 immunoreactivity on phagocytes 5 days post the last DT treatment. MOG-immunized CD169-DTR animals were treated every other 5 days (arrows) starting 5 dpi with PBS (n = 4; black) or diphtheria toxin (DT, n = 8). Neurological score and weight was assessed daily. Data represent the mean ± SEM. (d) The cumulative disease index and (e) disease onset of immunized CD169-DTR mice treated with PBS or DT. Data represent the mean ± SEM.
    Figure Legend Snippet: Figure 2. Transient depletion of CD169-expressing cells reduces EAE severity. (a) CD169-DTR mice and WT mice were sacrificed 2 or 8 days after intraperitoneal DTR administration. Splenic sections were stained with CD169 and DAPI (20× magnification). One representative image is shown. (b) Spinal cord tissue of PBS- and DT-treated CD169- DTR EAE animals (30 dpi) stained for CD169 and CD11b/c (20× magnification). EAE animals were treated with PBS or DT every other 5 days, starting 5 dpi. (c) Images show CD169 immunoreactivity on phagocytes 5 days post the last DT treatment. MOG-immunized CD169-DTR animals were treated every other 5 days (arrows) starting 5 dpi with PBS (n = 4; black) or diphtheria toxin (DT, n = 8). Neurological score and weight was assessed daily. Data represent the mean ± SEM. (d) The cumulative disease index and (e) disease onset of immunized CD169-DTR mice treated with PBS or DT. Data represent the mean ± SEM.

    Techniques Used: Expressing, Staining

    Figure 3. The number of circulating CD169+ phagocytes is increased in MS patients. (a and b) PBMCs isolated from MS patients (n = 57) and healthy controls (n = 19) were stained for CD14 and CD169. Flow cytometry was used to assess (a) the percentage of CD14+ cells expressing CD169 and (b) the abundance of CD169 on these cells. MS patients were subdivided based on their treatment regime: no treatment (n = 19), natalizumab (n = 10), beta-interferon (n = 22), and alemtuzumab (n = 6). Data are presented as mean ± SEM.
    Figure Legend Snippet: Figure 3. The number of circulating CD169+ phagocytes is increased in MS patients. (a and b) PBMCs isolated from MS patients (n = 57) and healthy controls (n = 19) were stained for CD14 and CD169. Flow cytometry was used to assess (a) the percentage of CD14+ cells expressing CD169 and (b) the abundance of CD169 on these cells. MS patients were subdivided based on their treatment regime: no treatment (n = 19), natalizumab (n = 10), beta-interferon (n = 22), and alemtuzumab (n = 6). Data are presented as mean ± SEM.

    Techniques Used: Isolation, Staining, Flow Cytometry, Expressing

    Figure 4. CD169 is highly expressed in MS brain tissue. (a–g) CNS tissue of non-neurological controls (white matter) and (chronic) active MS lesions were stained for CD169. Overview images of (a) an active and (b) chronic active MS lesion (2.5× magnification). (c) NAWM of non-demented control stained for CD169 (40× magnification). Representative images of (d) perilesional area of active MS lesion, (e) lesion center of active MS lesion, (f) perivascular cuff of active MS lesion, (g) active rim of chronic active MS lesion, and (h) inactive center of chronic active MS lesion (all 40× magnification).
    Figure Legend Snippet: Figure 4. CD169 is highly expressed in MS brain tissue. (a–g) CNS tissue of non-neurological controls (white matter) and (chronic) active MS lesions were stained for CD169. Overview images of (a) an active and (b) chronic active MS lesion (2.5× magnification). (c) NAWM of non-demented control stained for CD169 (40× magnification). Representative images of (d) perilesional area of active MS lesion, (e) lesion center of active MS lesion, (f) perivascular cuff of active MS lesion, (g) active rim of chronic active MS lesion, and (h) inactive center of chronic active MS lesion (all 40× magnification).

    Techniques Used: Staining, Control

    Figure 5. CD169 is highly expressed on myelin-containing phagocytes in MS lesions. (a) Fluorescent staining of active MS lesion (green, Iba1; red; CD169; 20× magnification). (b) Fluorescent staining of active MS lesion (green, PLP; red; CD169; 20× magnification). (c) Quantification of the percentage of Iba1+ cells expressing CD169 in active MS lesions. For quantification, 10 images per tissue or MS lesions were used (20× magnification). Data are presented as mean ± SEM.
    Figure Legend Snippet: Figure 5. CD169 is highly expressed on myelin-containing phagocytes in MS lesions. (a) Fluorescent staining of active MS lesion (green, Iba1; red; CD169; 20× magnification). (b) Fluorescent staining of active MS lesion (green, PLP; red; CD169; 20× magnification). (c) Quantification of the percentage of Iba1+ cells expressing CD169 in active MS lesions. For quantification, 10 images per tissue or MS lesions were used (20× magnification). Data are presented as mean ± SEM.

    Techniques Used: Staining, Expressing



    Similar Products

    mouse anti human cd169 fitc  (Bio-Rad)
    92
    Bio-Rad mouse anti human cd169 fitc
    Figure 1. <t>CD169-expressing</t> phagocytes are increased in the circulation and CNS of EAE animals. (a and b) Spinal cord tissue of EAE animals (20 dpi) stained for (a) CD169 and Iba1 or (b) CD169 and CD11b/c (both 20× magnification). (c) Spinal cord tissue of EAE animals (30 dpi) stained for CD169 and Iba1 (40× magnification). (d) Quantification of the amount of CD169+ cells per image and (e) the percentage of Iba1+ cells expressing CD169 in spinal cord tissue of control and EAE mice (acute (20 dpi) and chronic phase (30 dpi)). For quantification, 20 images per animal with 9 animals per time point were used (20× magnification). (f and g) PBMC isolated from control (n = 7) and EAE mice (acute phase (20 dpi), n = 6; chronic phase (30 dpi), n = 9) were stained for CD14 and CD169. Flow cytometry was used to assess the (f) % of CD14+ cells expressing CD169 and (g) the abundance of CD169 on these cells. Data are presented as mean ± SEM.
    Mouse Anti Human Cd169 Fitc, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human cd169 fitc/product/Bio-Rad
    Average 92 stars, based on 1 article reviews
    mouse anti human cd169 fitc - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. CD169-expressing phagocytes are increased in the circulation and CNS of EAE animals. (a and b) Spinal cord tissue of EAE animals (20 dpi) stained for (a) CD169 and Iba1 or (b) CD169 and CD11b/c (both 20× magnification). (c) Spinal cord tissue of EAE animals (30 dpi) stained for CD169 and Iba1 (40× magnification). (d) Quantification of the amount of CD169+ cells per image and (e) the percentage of Iba1+ cells expressing CD169 in spinal cord tissue of control and EAE mice (acute (20 dpi) and chronic phase (30 dpi)). For quantification, 20 images per animal with 9 animals per time point were used (20× magnification). (f and g) PBMC isolated from control (n = 7) and EAE mice (acute phase (20 dpi), n = 6; chronic phase (30 dpi), n = 9) were stained for CD14 and CD169. Flow cytometry was used to assess the (f) % of CD14+ cells expressing CD169 and (g) the abundance of CD169 on these cells. Data are presented as mean ± SEM.

    Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

    Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

    doi: 10.1177/1352458517698759

    Figure Lengend Snippet: Figure 1. CD169-expressing phagocytes are increased in the circulation and CNS of EAE animals. (a and b) Spinal cord tissue of EAE animals (20 dpi) stained for (a) CD169 and Iba1 or (b) CD169 and CD11b/c (both 20× magnification). (c) Spinal cord tissue of EAE animals (30 dpi) stained for CD169 and Iba1 (40× magnification). (d) Quantification of the amount of CD169+ cells per image and (e) the percentage of Iba1+ cells expressing CD169 in spinal cord tissue of control and EAE mice (acute (20 dpi) and chronic phase (30 dpi)). For quantification, 20 images per animal with 9 animals per time point were used (20× magnification). (f and g) PBMC isolated from control (n = 7) and EAE mice (acute phase (20 dpi), n = 6; chronic phase (30 dpi), n = 9) were stained for CD14 and CD169. Flow cytometry was used to assess the (f) % of CD14+ cells expressing CD169 and (g) the abundance of CD169 on these cells. Data are presented as mean ± SEM.

    Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

    Techniques: Expressing, Staining, Control, Isolation, Flow Cytometry

    Figure 2. Transient depletion of CD169-expressing cells reduces EAE severity. (a) CD169-DTR mice and WT mice were sacrificed 2 or 8 days after intraperitoneal DTR administration. Splenic sections were stained with CD169 and DAPI (20× magnification). One representative image is shown. (b) Spinal cord tissue of PBS- and DT-treated CD169- DTR EAE animals (30 dpi) stained for CD169 and CD11b/c (20× magnification). EAE animals were treated with PBS or DT every other 5 days, starting 5 dpi. (c) Images show CD169 immunoreactivity on phagocytes 5 days post the last DT treatment. MOG-immunized CD169-DTR animals were treated every other 5 days (arrows) starting 5 dpi with PBS (n = 4; black) or diphtheria toxin (DT, n = 8). Neurological score and weight was assessed daily. Data represent the mean ± SEM. (d) The cumulative disease index and (e) disease onset of immunized CD169-DTR mice treated with PBS or DT. Data represent the mean ± SEM.

    Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

    Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

    doi: 10.1177/1352458517698759

    Figure Lengend Snippet: Figure 2. Transient depletion of CD169-expressing cells reduces EAE severity. (a) CD169-DTR mice and WT mice were sacrificed 2 or 8 days after intraperitoneal DTR administration. Splenic sections were stained with CD169 and DAPI (20× magnification). One representative image is shown. (b) Spinal cord tissue of PBS- and DT-treated CD169- DTR EAE animals (30 dpi) stained for CD169 and CD11b/c (20× magnification). EAE animals were treated with PBS or DT every other 5 days, starting 5 dpi. (c) Images show CD169 immunoreactivity on phagocytes 5 days post the last DT treatment. MOG-immunized CD169-DTR animals were treated every other 5 days (arrows) starting 5 dpi with PBS (n = 4; black) or diphtheria toxin (DT, n = 8). Neurological score and weight was assessed daily. Data represent the mean ± SEM. (d) The cumulative disease index and (e) disease onset of immunized CD169-DTR mice treated with PBS or DT. Data represent the mean ± SEM.

    Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

    Techniques: Expressing, Staining

    Figure 3. The number of circulating CD169+ phagocytes is increased in MS patients. (a and b) PBMCs isolated from MS patients (n = 57) and healthy controls (n = 19) were stained for CD14 and CD169. Flow cytometry was used to assess (a) the percentage of CD14+ cells expressing CD169 and (b) the abundance of CD169 on these cells. MS patients were subdivided based on their treatment regime: no treatment (n = 19), natalizumab (n = 10), beta-interferon (n = 22), and alemtuzumab (n = 6). Data are presented as mean ± SEM.

    Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

    Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

    doi: 10.1177/1352458517698759

    Figure Lengend Snippet: Figure 3. The number of circulating CD169+ phagocytes is increased in MS patients. (a and b) PBMCs isolated from MS patients (n = 57) and healthy controls (n = 19) were stained for CD14 and CD169. Flow cytometry was used to assess (a) the percentage of CD14+ cells expressing CD169 and (b) the abundance of CD169 on these cells. MS patients were subdivided based on their treatment regime: no treatment (n = 19), natalizumab (n = 10), beta-interferon (n = 22), and alemtuzumab (n = 6). Data are presented as mean ± SEM.

    Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

    Techniques: Isolation, Staining, Flow Cytometry, Expressing

    Figure 4. CD169 is highly expressed in MS brain tissue. (a–g) CNS tissue of non-neurological controls (white matter) and (chronic) active MS lesions were stained for CD169. Overview images of (a) an active and (b) chronic active MS lesion (2.5× magnification). (c) NAWM of non-demented control stained for CD169 (40× magnification). Representative images of (d) perilesional area of active MS lesion, (e) lesion center of active MS lesion, (f) perivascular cuff of active MS lesion, (g) active rim of chronic active MS lesion, and (h) inactive center of chronic active MS lesion (all 40× magnification).

    Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

    Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

    doi: 10.1177/1352458517698759

    Figure Lengend Snippet: Figure 4. CD169 is highly expressed in MS brain tissue. (a–g) CNS tissue of non-neurological controls (white matter) and (chronic) active MS lesions were stained for CD169. Overview images of (a) an active and (b) chronic active MS lesion (2.5× magnification). (c) NAWM of non-demented control stained for CD169 (40× magnification). Representative images of (d) perilesional area of active MS lesion, (e) lesion center of active MS lesion, (f) perivascular cuff of active MS lesion, (g) active rim of chronic active MS lesion, and (h) inactive center of chronic active MS lesion (all 40× magnification).

    Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

    Techniques: Staining, Control

    Figure 5. CD169 is highly expressed on myelin-containing phagocytes in MS lesions. (a) Fluorescent staining of active MS lesion (green, Iba1; red; CD169; 20× magnification). (b) Fluorescent staining of active MS lesion (green, PLP; red; CD169; 20× magnification). (c) Quantification of the percentage of Iba1+ cells expressing CD169 in active MS lesions. For quantification, 10 images per tissue or MS lesions were used (20× magnification). Data are presented as mean ± SEM.

    Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

    Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

    doi: 10.1177/1352458517698759

    Figure Lengend Snippet: Figure 5. CD169 is highly expressed on myelin-containing phagocytes in MS lesions. (a) Fluorescent staining of active MS lesion (green, Iba1; red; CD169; 20× magnification). (b) Fluorescent staining of active MS lesion (green, PLP; red; CD169; 20× magnification). (c) Quantification of the percentage of Iba1+ cells expressing CD169 in active MS lesions. For quantification, 10 images per tissue or MS lesions were used (20× magnification). Data are presented as mean ± SEM.

    Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

    Techniques: Staining, Expressing